CDH1变异所致遗传性小叶乳腺癌与胃癌风险关联
这项前瞻性队列研究纳入283例携带CDH1致病或可能致病变异的患者,按家族史分为遗传性小叶乳腺癌组、遗传性弥漫性胃癌组和混合组。
要点
- CDH1致病变异携带者无论有无胃癌家族史,隐匿性印戒细胞胃癌风险均高。
- 遗传性小叶乳腺癌组预防性全胃切除后病理检出隐匿癌的比例为93.8%。
核心结论
- 携带CDH1致病或可能致病变异且无胃癌家族史的患者仍表现出高比例的隐匿性印戒细胞胃癌。
- CDH1种系致病变异似乎具有高度外显的胃癌表型,与家族史无关。
研究设计与样本
- 前瞻性队列研究,纳入2017年10月至2021年1月在一家四级医疗中心登记的283例CDH1致病或可能致病变异患者,来自151个家庭。
- 按家族史分为三组:遗传性小叶乳腺癌组(44/283,15.5%)、遗传性弥漫性胃癌组(46/283,16.2%)和混合组(193/283,68.2%)。
- 中位年龄48岁(范围18-81岁),女性199例(70.3%),白人259例(91.5%)。
主要发现
- 遗传性小叶乳腺癌组包含31个不同家庭和19种CDH1变异,其中10种变异(52.6%)也存在于遗传性弥漫性胃癌组和混合组。
- 遗传性小叶乳腺癌组中接受预防性全胃切除的患者,最终病理检出隐匿性印戒细胞胃癌的比例为93.8%(15/16种变异),中位年龄50岁(范围21-67岁)。
临床怎么用
- 对于携带CDH1致病或可能致病变异、被认定为遗传性小叶乳腺癌的患者,即使无胃癌家族史,也应告知其高胃癌风险。
- 此类患者可考虑纳入遗传性弥漫性胃癌的监测或预防性全胃切除决策框架。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hereditary cancer risk is informed by the presence of a germline gene variant more so than by family history of cancer. OBJECTIVE: To assess gastric cancer risk among patients who received a diagnosis of hereditary lobular breast cancer (HLBC) owing to a germline loss-of-function variant in CDH1 by establishing prevalence of signet ring cell carcinomas among asymptomatic patients. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study of patients with germline CDH1 pathogenic or likely pathogenic (P/LP) variants at a quaternary medical center were enrolled between October 2017 and January 2021. Data analysis was performed in May 2021. Analyses for associations were performed for these 3 patient groups: (1) family history of breast cancer and no gastric cancer in the HLBC group; (2) family history of gastric cancer and no breast cancer in the hereditary diffuse gastric cancer (HDGC) group; and (3) family history of both breast and gastric cancers in the mixed group. Categorical variables were compared using the Pearson χ2 test. MAIN OUTCOMES AND MEASURES: The primary end point of this study was the prevalence of occult signet ring cell carcinoma of the stomach in patients with HLBC. Personal and family medical history, genotype, and pathologic data from risk-reducing total gastrectomy and surveillance endoscopy were examined. RESULTS: A total of 283 patients with CDH1 P/LP variants (199 [70.3%] were female, and 259 [91.5%] were White; median age, 48 years [range, 18-81 years]) were enrolled in a prospective study of HDGC. The cohort consisted of 151 families. Patients were categorized according to family history of breast and/or gastric cancer: HLBC 15.5% [44 of 283 patients]), HDGC (16.2% [46 of 283 patients]), and mixed (68.2% [193 of 283 patients]). The HLBC group included 31 distinct families with 19 CDH1 variants; 10 of those variants were also present in the HDGC and mixed groups (52.6% [10 of 19 variants]). Nearly all of the patients with HLBC (93.8% [15 of 16 variants]) who elected for risk-reducing total gastrectomy owing to their underlying CDH1 P/LP variant harbored occult signet ring cell gastric adenocarcinoma on final pathology (median age, 50 years [range, 21-67 years]). The prevalence of occult gastric cancer among asymptomatic patients in the HDGC group was similar (94.7% [18 of 19 of variants]; P = .98). CONCLUSIONS AND RELEVANCE: Carriers of CDH1 P/LP variants with no family history of gastric cancer exhibited high rates of occult signet ring cell gastric cancer. Germline CDH1 P/LP variants appear to have a highly penetrant gastric phenotype irrespective of family history. These data may prove useful for counseling families with CDH1 variants presumed to have HLBC.
引用
- Gamble LA, Rossi A, Fasaye GA, et al. Association Between Hereditary Lobular Breast Cancer Due to CDH1 Variants and Gastric Cancer Risk. JAMA Surg. 2022. PMID: 34643667. doi:10.1001/jamasurg.2021.5118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。